Health & Medicine The Drug Combo That's Giving Pancreatic Cancer Patients New Hope Atebimetinib combination therapy achieves compelling one-year survival rates in pancreatic cancer patients, offering new hope for historically treatment-resistant disease.
Health & Medicine The Cancer Combo That's Rewriting Early Treatment Success Rates KEYTRUDA-WELIREG combination reduces kidney cancer death risk by 28% in groundbreaking Phase 3 trial, earning FDA priority review status.